Cigna earnings beat by $0.04, revenue topped estimates
Catheter Precision, Inc. (NYSE:VTAK), a micro-cap medical device company with a market capitalization of $2.31 million, announced a significant change in its executive team earlier this week. On Monday, Marie-Claude Jacques, the company’s Chief Commercial Officer, departed from her role. In response to this change, David Jenkins, who serves as the Executive Chairman of the Board and Chief Executive Officer, will temporarily assume the responsibilities of Chief Commercial Officer until a replacement is appointed.
The company, which is incorporated in Delaware and operates in the surgical and medical instruments sector, made this announcement through a filing with the Securities and Exchange Commission (SEC). The filing, known as a Form 8-K, is used by publicly traded companies to disclose major events that shareholders should be aware of. According to InvestingPro data, the company maintains impressive gross profit margins of 90%, though it faces challenges with cash burn rates.
Catheter Precision, previously known as Ra Medical (TASE:BLWV) Systems, Inc., is headquartered in Fort Mill, South Carolina. The company is not classified as an emerging growth company under the SEC’s definitions.
This leadership transition follows the company’s continued efforts to strengthen its executive team and maintain its position in the medical device industry. The company’s shares are traded on the NYSE American under the ticker symbol VTAK.
The announcement was based on a press release statement filed with the SEC.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.